A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Crinetics Pharmaceuticals Inc.
Study ID
NCT07129252
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • CRN09682 — DRUG
    Study drug CRN09682 intravenously

Study Details

This Phase 1/2, multicenter, open-label, FIH study aims to evaluate the safety, tolerability, PK, and preliminary antitumor activity of CRN09682 in participants with SST2-expressing NENs and other solid tumors. The study includes a Dose Escalation Phase to determine the MTD and DLTs. Following MTD identification, additional participants will be enrolled at the expansion dose to further assess safety, tolerability, PK, and antitumor activity.

Key Dates

Start date
Nov 26, 2025
Status verified
Mar 2026
Primary completion
Aug 31, 2027
Completion
Aug 31, 2029

Study Design

Enrollment
150 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Dose Escalation
    Multiple Dose Levels administered Q3W
  • Experimental: Dose Expansion: Cohort 1
    Pancreatic Neuroendocrine Tumor (NET)
  • Experimental: Dose Expansion: Cohort 2
    Non-Pancreatic NET
  • Experimental: Dose Expansion: Cohort 3
    Neuroendocrine Carcinoma (NEC)
  • Experimental: Dose Expansion: Cohort 4
    Other Solid Tumors

Primary Outcome Measure

(Dose Escalation) Incidence and severity of DLTs. [ Time Frame: From first dose through Day 21. ]

Central Contacts

Locations (20)

FacilityCityStateZIPSite coordinators
Crinetics Study SitePhoenixArizona85054-
Crinetics Study SiteDuarteCalifornia91010-
Crinetics Study SiteNewport BeachCalifornia92663-
Crinetics Study SiteOrangeCalifornia92868-
Crinetics Study SiteSan FranciscoCalifornia60637-
Crinetics Study SiteDenverColorado80218-
Crinetics Study SiteNew HavenConnecticut48201-
Crinetics Study SiteAtlantaGeorgia30322-
Crinetics Study SiteLexingtonKentucky40536-
Crinetics Study SiteMetairieLouisiana70006-
Crinetics Study SiteDetroitMichigan48201-
Crinetics Study SiteGrand RapidsMichigan49503-
Crinetics Study SiteRochesterMinnesota53905-
Crinetics Study SitePhiladelphiaPennsylvania19111-
Crinetics Study SiteAustinTexas78758-
Crinetics Study SiteHoustonTexas70030-
Crinetics Study SiteIrvingTexas75039-
Crinetics Study SiteSalt Lake CityUtah84112-
Crinetics Study SiteCharlottesvilleVirginia22908-
Crinetics Study SiteFairfaxVirginia22031-

Find similar trials in Phoenix, AZ

By condition
Neuroendocrine tumors
By specialty
Oncology
By research site
Crinetics Study Site· Phoenix, AZCrinetics Study Site· Duarte, CACrinetics Study Site· Newport Beach, CACrinetics Study Site· Orange, CACrinetics Study Site· San Francisco, CACrinetics Study Site· Denver, CO

Related Studies